Indian pharmaceutical company Hetero Drugs has received emergency use approval from the country's health authorities to make a generic version of Swiss healthcare company Roche Holding AG's (SWX:ROG.S) COVID-19 drug, tocilizumab, Reuters news agency reported on Monday.
Hetero expects to make tocilizumab available in India by the end of the month under the brand name Tocira.
It will reportedly be made by Hetero's unit at its Hyderabad facility.
Roche's arthritis drug, tocilizumab, cuts the risk of death among patients hospitalised with severe COVID-19 along with shortening the recovery time and reducing the need for mechanical ventilation.
Kazia Therapeutics' paxalisib receives Orphan Drug Designation from FDAQ
Dr. Reddy's Laboratories Launches Pemetrexed for Injection USP, in the US Market
Accord Healthcare introduces Pemetrexed Lyo. Injection to range of chemotherapy drugs
Astellas receives unfavourable decision in LEXISCAN(R) 0.4mg/mL US patent trial
Famotidine (Pepcid) Activates the Vagus Nerve to Reduce Cytokine Storm in COVID-19, New Study Shows